ArticleInternational ophthalmology2024
Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome.
Article in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the short and mid-term outcomes of epithelium-off (epi-off) corneal collagen cross-linking using Riboflavin with Vitamin E TPGS (Epi-off Ribocross® CXL) for progressive keratoconus (KC).
designRetrospective, single-center non-comparative interventional study.
methodsPatients with progressive keratoconus who underwent CXL using (Epi-off Ribocross® CXL) from May 2021 to May 2022 who completed at least 12 months of follow-up in Humanitas Clinical and Research Center, Rozzano, Milan, Italy. Corrected distance visual acuity with spectable (CDVA), tomographic parameters (Belin ABCD) and topographic parameters were evaluated at baseline and at last follow up.
resultsTwenty eyes of twenty patients fulfilled inclusion criteria. CDVA remained stable at last follow up (0.88 ± 0.19 from 0.83 ± 0.21, p = 0.45) with a significant reduction in cylinder (1.97 ± 1.69 from 2.78 ± 2.19, p = 0.03). Kmax significantly improved from 53.18D ± 6.32 to 50.96 ± 5.3D (p = 0.005). At the last follow up, no case of progression was noted.
conclusionsEpi-off Ribocross® CXL proved to be a safe treatment for progressive KC, with a stabilization of all cases at the one year follow up. Further studies are needed to confirm long-term stability.
Indexed as
Identifiers
39537985What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.